Search - tctmd.com

Displaying 681 - 700 of 3208

Sort: Relevancy | Date

News Daily News

Actualización de la Directriz Impulsa la PCI de la Arteria no Causante y Saca de la Pelea a la Trombectomía por Aspiración

Todd Neale

October 26, 2015

News Industry News

One-Year Outcomes From the COMBO REMEDEE All-Comers Registry Presented at TCT 2015

October 20, 2015

News Industry News

FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa

October 20, 2015

News Conference News TCT 2015

IBIS-4: Rosuvastatin Tied to Plaque Stability in STEMI

Yael L. Maxwell

October 16, 2015

Presentation TCT 2015

Vorapaxar: Lessons From the Randomized Trials in ACS and for Secondary Prevention

Presenter: Eric R. Bates, Neal S. Kleiman, Ori Ben-Yehuda

October 15, 2015

Presentation TCT 2015

MATRIX Trial Recap: Interaction Between Access Site and Antithrombin Choice in ACS

Presenter: Carlo Briguori, Roxana Mehran

October 15, 2015

Presentation TCT 2015

Identification and Treatment of High-Risk Lesion(s) in ACS With OCT Guidance

Presenter: Takashi Akasaka, Giulio Guagliumi, Takashi Kubo

October 15, 2015

News Industry News

Similar Results With Bivalirudin Compared With Heparin Anticoagulation In TAVR Patients

October 15, 2015

News Conference News TCT 2015

BRAVO 3: Bivalirudin Similar to Heparin in Transfemoral TAVR

Yael L. Maxwell

October 15, 2015

Presentation TCT 2015

The PIONEER Trial (Rivaroxaban in Patients With ACS and Atrial Fibrillation): Design, Rationale, and Status

Presenter: Pascal Vranckx, Roxana Mehran

October 14, 2015

Presentation TCT 2015

The RE-DUAL PCI Trial (Dabigatran in Patients With ACS and Atrial Fibrillation): Design, Rationale, and Status

Presenter: Pascal Vranckx, Deepak L. Bhatt

October 14, 2015

Presentation TCT 2015

A Trial of Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status

Presenter: Pascal Vranckx, Renato D. Lopes

October 14, 2015

Presentation TCT 2015

Can We Drop Aspirin? Pharmacodynamic Insights on Adding an Oral Anticoagulant to Antiplatelet Therapy With and Without Aspirin

Presenter: Pascal Vranckx, Freek W.A. Verheugt

October 14, 2015

Presentation TCT 2015

Update on the ACST-2 Trial: Early Outcomes and Perspectives on the Field From Across the Pond

Presenter: William A. Gray, D. Christopher Metzger, Bernhard Reimers

October 14, 2015

Presentation TCT 2015

ACS/PCI Guidelines and AUC Update: Hitting the Highlights

Presenter: Larry S. Dean, Simon R. Dixon, Manesh R. Patel

October 14, 2015

News Conference News TCT 2015

TUXEDO-India Affirms Superiority of EES in Patients With Diabetes

Todd Neale

October 14, 2015

News Conference News TCT 2015

PANDA III: BuMA SES Noninferior to Excel SES for TLF at 1 Year

October 14, 2015

News Conference News TCT 2015

MASTER: Positive Results Seen for Bioresorbable-Polymer DES in STEMI

October 14, 2015

News Conference News TCT 2015

Manual Thrombectomy Does Not Improve Outcomes in High-Risk STEMI Patients

October 14, 2015

News Conference News TCT 2015

LEADERS FREE: Drug-Coated Stent Bests BMS in High-Risk PCI Patients

Yael L. Maxwell

October 14, 2015

Advertisement

Actualización de la Directriz Impulsa la PCI de la Arteria no Causante y Saca de la Pelea a la Trombectomía por Aspiración

One-Year Outcomes From the COMBO REMEDEE All-Comers Registry Presented at TCT 2015

FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa

IBIS-4: Rosuvastatin Tied to Plaque Stability in STEMI

Vorapaxar: Lessons From the Randomized Trials in ACS and for Secondary Prevention

MATRIX Trial Recap: Interaction Between Access Site and Antithrombin Choice in ACS

Identification and Treatment of High-Risk Lesion(s) in ACS With OCT Guidance

Similar Results With Bivalirudin Compared With Heparin Anticoagulation In TAVR Patients

BRAVO 3: Bivalirudin Similar to Heparin in Transfemoral TAVR

The PIONEER Trial (Rivaroxaban in Patients With ACS and Atrial Fibrillation): Design, Rationale, and Status

The RE-DUAL PCI Trial (Dabigatran in Patients With ACS and Atrial Fibrillation): Design, Rationale, and Status

A Trial of Apixaban in Patients With Atrial Fibrillation and ACS/PCI: Design, Rationale, and Status

Can We Drop Aspirin? Pharmacodynamic Insights on Adding an Oral Anticoagulant to Antiplatelet Therapy With and Without Aspirin

Update on the ACST-2 Trial: Early Outcomes and Perspectives on the Field From Across the Pond

ACS/PCI Guidelines and AUC Update: Hitting the Highlights

TUXEDO-India Affirms Superiority of EES in Patients With Diabetes

PANDA III: BuMA SES Noninferior to Excel SES for TLF at 1 Year

MASTER: Positive Results Seen for Bioresorbable-Polymer DES in STEMI

Manual Thrombectomy Does Not Improve Outcomes in High-Risk STEMI Patients

LEADERS FREE: Drug-Coated Stent Bests BMS in High-Risk PCI Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content